Brief: Humacyte Atev Met Superiority Primary Endpoint Compared To Standard Of Care Av Fistula In Interim Analysis Of V012 Phase 3 Study In Female Dialysis Access Patients
10/06/2026 21:28
BRIEF-Humacyte Atev Met Superiority Primary Endpoint Compared To Standard Of Care Av Fistula In Interim Analysis Of V012 Phase 3 Study In Female Dialysis Access Patients June 10 (Reuters) - Humacyte Inc HUMA.O:
HUMACYTE ATEV MET SUPERIORITY PRIMARY ENDPOINT COMPARED TO STANDARD OF CARE AV FISTULA IN INTERIM ANALYSIS OF V012 PHASE 3 STUDY IN FEMALE DIALYSIS ACCESS PATIENTS
HUMACYTE - TO FILE SUPPLEMENTAL BLA WITH FDA IN SECOND HALF OF 2026
HUMACYTE - STUDY ENROLLMENT TO TERMINATE AFTER MEETING PRIMARY ENDPOINT
Source text: ID:nGNX8ZbM72
Further company coverage: HUMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Humacyte
See all newsBrief: Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Humacyte falls after wider-than-expected quarterly loss
Humacyte Inc reports results for the quarter ended June 30 - Earnings Summary